Menopause is the one point in adult life where skin changes on a measurable schedule, and the skincare aisle has noticed: "menopause skin care" is now a shelf of its own. This page sets out what the research has measured about skin after menopause, what the hormone trials found, and what has and has not been tested for peptides. It does not recommend a product or a treatment.
For the hormonal side of menopause — the hot-flush drugs and the peptide hormones behind them — Peptide Lexicon's peptides for menopause entry covers the evidence; this page stays with the skin.
What changes, and how fast
The figure most often repeated about menopause and skin comes from a series of studies at a London menopause clinic in the 1980s. Measuring skin collagen content, skin thickness, the metacarpal index and forearm bone mineral content in postmenopausal women, Brincat and colleagues found that all four declined at a similar rate of between 1 and 2 percent a year after the menopause, and that the declines correlated with each other (Obstetrics and Gynecology, 1987, PMID 3120067). A companion study measured thigh-skin collagen in 69 untreated women and 37 who had been on estradiol and testosterone implants for 2 to 10 years: collagen fell with years since menopause in the untreated group, and the decline was not seen in the treated group (British Journal of Obstetrics and Gynaecology, 1987, PMID 3828252).
Those were cross-sectional comparisons, not trials: women on hormones may differ from women who are not in other ways. Their importance is that they tied skin and bone to the same connective-tissue loss, which is why the skin question has been studied by gynaecologists as much as by dermatologists.
What the hormone trials measured
| Trial | Who | What was given | Measured | Result |
|---|---|---|---|---|
| Castelo-Branco et al., Maturitas 1992 (PMID 1345134) | 118 postmenopausal women, randomized to four groups | hormone replacement regimens vs control, 12 months | 312 abdominal skin biopsies | collagen rose on every regimen; fell in controls |
| Silva et al., Gynecol Endocrinol 2017 (PMID 28508697) | 30 women aged 45–55, not on systemic hormones | topical estradiol vs topical genistein (a soy isoflavone), 24 weeks, double-blind | pre-auricular facial biopsies | type I and III collagen rose in both; estradiol larger |
| Draelos, J Drugs Dermatol 2018 (PMID 30500138) | postmenopausal women who had never taken hormones | methyl estradiolpropanoate, an estrogen-like ingredient designed to break down in the skin, vs vehicle, 14 weeks | investigator grading; 9-person biopsy substudy | dryness, laxity, atrophy and dullness improved vs vehicle |
The pattern is consistent: in the trials that took biopsies, estrogen given by mouth, by implant or on the skin was followed by more skin collagen than no treatment. Two limits bind it. These are small studies, two of them decades old, measuring collagen rather than appearance over years. And hormone therapy is a prescription treatment taken for menopausal symptoms and bone, with risks that have to be weighed by a doctor; no one prescribes it for skin, and nothing here suggests otherwise.
What has been tested for peptides
A PubMed search run on 2 November 2026 joined menopause, postmenopause or perimenopause with skin or facial, with peptide, and with topical, cream, serum or cosmetic. It returned 8 records, every title read:
- one 2026 round-table review on aesthetic treatment around menopause;
- one 2023 randomized trial of oral and topical collagen peptides in postmenopausal women with fragile skin (below);
- one 2025 randomized trial of oral collagen with calcium and vitamin D, whose primary measures were bone markers;
- five papers in which "peptide" means something else — calcitonin gene-related peptide in a fibromyalgia blood-flow study and in ovariectomized rats, a parathyroid-hormone fusion protein in mice, insulin-resistance models in polycystic ovary syndrome, and a 1984 naloxone hot-flush study.
No trial of a topical cosmetic peptide — palmitoyl pentapeptide-4, acetyl hexapeptide-8, copper tripeptide-1 or any other — in postmenopausal skin is in the index. The peptide serums sold for menopausal skin rest on trials in mixed-age adults, where they exist at all; our peptides for wrinkles page counts those.
The collagen trial is worth reading in full because it is negative. Guadanhim and colleagues randomized 56 postmenopausal women aged 60 to 93 with stage I dermatoporosis — thinned, fragile forearm skin — to oral collagen hydrolysate (5 g a day) or placebo, and separately to a 2.5% topical collagen serum or placebo, for six months. Nothing differed: not clinical scores, quality of life, elasticity, thickness or echogenicity on ultrasound, or the biopsy markers (Dermatology and Therapy, 2023, PMID 36547800). The authors concluded the products should not be used routinely in that group. It is one trial in older women, but it is the only randomized peptide trial in postmenopausal skin.
The "menopause skincare" shelf
Products sold for menopausal skin are a marketing category, not a regulated one; no cosmetic is approved to treat menopause. The trials behind them are small and sponsored. One example: a 2026 open-label study of a 13-adaptogen serum in perimenopausal and postmenopausal women reported improvements in lines, crepiness and hydration over 16 weeks, with no comparison group and one author employed by the brand (J Cosmet Dermatol, PMID 42117281). Its entry criteria required participants to stop using topical peptides, retinoids and growth factors for two weeks beforehand — a reminder that in a trial, peptides are treated as an active to wash out, not as the thing being tested.
For skin that has gone thin and finely wrinkled, which often accompanies the later postmenopausal years, our crepey skin page counts the body-cream trials; for the elastin side, see elastin peptides.
What can fairly be said
- Skin collagen and thickness fall after menopause, by roughly 1 to 2 percent a year in the studies that first measured it.
- Hormone therapy, oral, implanted or topical, was followed by more skin collagen in small biopsy trials; it is prescribed for other reasons, and the decision belongs with a doctor.
- No topical cosmetic peptide has been trialled in postmenopausal skin, and the one randomized collagen-peptide trial there found no effect.
- What is not established is whether any over-the-counter product changes menopausal skin beyond what moisturizing does. A woman weighing hormone therapy, a prescription retinoid or a procedure has a question for her doctor or a dermatologist.
Sources
Opened 2 November 2026: PubMed E-utilities searches (menopaus*[tiab] OR postmenopaus*[tiab] OR perimenopaus*[tiab]) AND (skin[tiab] OR facial[tiab]) AND peptide*[tiab] AND (topical[tiab] OR cream[tiab] OR serum[tiab] OR cosmetic*[tiab]) (8 records, every title read) and (menopaus*[tiab] OR postmenopaus*[tiab]) AND skin[tiab] AND (estrogen*[tiab] OR "hormone replacement"[tiab] OR "hormone therapy"[tiab]) AND collagen[tiab] AND randomized controlled trial[pt] (6 records, every title read). Abstracts: Brincat M et al., Obstet Gynecol 1987, PMID 3120067; Brincat M et al., Br J Obstet Gynaecol 1987, PMID 3828252; Castelo-Branco C et al., Maturitas 1992, PMID 1345134; Silva LA et al., Gynecol Endocrinol 2017, PMID 28508697; Draelos ZD, J Drugs Dermatol 2018, PMID 30500138; Guadanhim LRS et al., Dermatol Ther (Heidelb) 2023, PMID 36547800; Duangjai A et al., Clin Pract 2025, PMID 41002783; Draelos ZD et al., J Cosmet Dermatol 2026, PMID 42117281 (washout criteria from PMC13162087). Peptide Lexicon, Peptides for menopause, read 2 November 2026. Corrections go to the contact page.